Drug intelligence / Profile preview

GM28K

Development stage: Preclinical
Lead developer: GreyMatter Pharma
Modality: Small Molecules

Overview

GM28K is a novel ketamine derivative being developed by Grey Matter Pharma for the treatment of Treatment-Resistant Depression (TRD). As a next-generation ketamine analog, it is designed to modulate the N-methyl-D-aspartate (NMDA) receptor, a mechanism validated by the success of esketamine in psychiatric care. The drug aims to provide rapid-acting antidepressant effects while potentially improving the safety, tolerability, or pharmacokinetic profile compared to traditional ketamine. It is currently in the early stages of development within Grey Matter Pharma's psychiatric pipeline.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on GM28K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM28K.

Explore the full profile